Generalized Pustular Psoriasis Drug Safety Registry
Part of Skin clinical trials.
This registry tracks the safety and effectiveness of GPP treatments in real-world settings. It helps doctors and researchers learn how well current and future medicines work for people with generalized pustular psoriasis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with GPP by a dermatologist or skin specialist.
- You are at least 18 years old and can give your consent to join.
- You are not currently in a blinded clinical trial for GPP treatment.
- You are not enrolled in another CorEvitas registry for a skin condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a registry in Costa Rica that collects information about people diagnosed with generalized pustular psoriasis (GPP). It helps doctors learn more about this rare skin condition and how it affects patients over time.
This registry collects information from adults with psoriasis to better understand how psoriasis affects people and how treatments are used in real life. It may help future research and improve knowledge about treatment patterns and outcomes.
This study follows patients with moderate to severe psoriasis who are starting a new advanced medication for the first time. Researchers will track how well the treatment works early on to understand what helps different patients improve.
This study follows people starting a new advanced psoriasis treatment to see how well it works over 16 weeks. You'll have three office visits with your dermatologist, and researchers will track your skin improvement to help understand which treatments work best for different patients.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This study looks at how well two common plaque psoriasis medicines—deucravacitinib and apremilast—work in everyday care. It may help researchers understand which option performs better in real patients outside of a traditional drug trial.
Hear when a new Generalized Pustular Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.